
Benzinga Pro data, Concert Pharmaceuticals (NASDAQ:CNCE) reported Q4 sales of $13.00 thousand. Earnings fell to a loss of $36.13 million, resulting in a 35.43% decrease from last quarter. In Q3, Concert Pharmaceuticals brought in $543.00 thousand in sales but lost $26.68 million in earnings.